---
layout: default
title: Dl-Threonine
parent: 僅模型預測 (L5)
nav_order: 177
evidence_level: L5
indication_count: 0
---

# Dl-Threonine
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# DL-Threonine: No Repurposing Prediction Generated — Hold Pending Data Resolution

---

## One-Sentence Summary

DL-Threonine is a racemic amino acid compound (equal mixture of L- and D-threonine enantiomers), with no current SAHPRA registration or confirmed approved indication on record.
The TxGNN model was **unable to generate any repurposing predictions** for this compound, as no DrugBank identifier was resolved and no original regulatory indications were available as input.
Without these foundational data elements, evidence-level classification and a clinical rationale cannot be established at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not available |
| Predicted New Indication | No prediction generated |
| TxGNN Prediction Score | N/A |
| Evidence Level | Not assignable — pipeline inputs missing |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | **Hold** |

---

## Why No Prediction Was Generated

The TxGNN repurposing pipeline requires two foundational inputs to function:

1. **A valid DrugBank ID** — used to locate the drug node within the knowledge graph (KG) and execute both KG-based and deep-learning (DL) predictions.
2. **At least one approved indication** — used to contextualise the drug's position within the drug–disease network.

For DL-Threonine, neither input was successfully resolved. No DrugBank ID was returned in this Evidence Pack, and the original indications list is empty. As a result, the TxGNN model had no entry point into the knowledge graph and no predictions were produced.

From general pharmacological knowledge, DL-Threonine is the racemic form of the essential amino acid threonine. The biologically active enantiomer, L-Threonine (DrugBank: DB00156), is involved in protein biosynthesis, intestinal mucosal integrity, hepatic lipid metabolism, and immune function. It is primarily used as a nutritional supplement or enteral feeding component rather than a conventional pharmaceutical. Whether the DL-racemic form warrants a separate repurposing evaluation — distinct from L-Threonine — is itself a question that requires pharmacological clarification before proceeding.

---

## South Africa Market Information

No SAHPRA-registered products were identified for DL-Threonine. This compound has no licensed pharmaceutical registrations in South Africa at this time.

If DL-Threonine is intended to be evaluated as a nutritional supplement or functional food ingredient rather than a registered medicine, a different regulatory pathway (e.g., Section 21 authorisation or Complementary Medicine framework) may be applicable.

---

## Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The TxGNN repurposing evaluation for DL-Threonine cannot proceed because the two critical pipeline inputs — DrugBank ID and approved indication — are both absent. There is no prediction score, no evidence trail, and no mechanism-of-action data to evaluate. Issuing a repurposing recommendation under these conditions would not be clinically meaningful.

**To proceed, the following is needed:**

- **Resolve the DrugBank ID**: Determine whether DL-Threonine maps to DB00156 (L-Threonine) or requires a distinct identifier. If the racemic form is not separately listed in DrugBank, consider evaluating L-Threonine as the primary entity.
- **Establish the original approved indication**: Retrieve product labelling from SAHPRA, TFDA, or an international reference authority (EMA, FDA, TGA) to confirm the registered therapeutic use.
- **Re-run the TxGNN pipeline**: Once DrugBank mapping and original indication are confirmed, re-submit for KG and DL predictions.
- **Clarify the clinical entity**: Confirm whether the target of this evaluation is DL-Threonine (racemic), L-Threonine (pure enantiomer), or a combination product containing threonine as an active component.
- **Obtain safety data**: Download and parse the approved PI document to populate warnings, contraindications, and drug interaction fields before any safety-based decision can be made.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

